Eliem Therapeutics (ELYM) Stock Price, News & Analysis

Company Overview

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Key Stats

• Today's Range: $1.86 to $2.07
• 50-Day Range: $1.95 to $5.44
• 52-Week Range: $2.35 to $11.55
• Volume: 1.47 million shs
• Average Volume: 486,688 shs
• Market Capitalization: $58.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ELYM Stock Analysis - Frequently Asked Questions

How have ELYM shares performed this year?

Eliem Therapeutics' stock was trading at $2.70 at the beginning of the year. Since then, ELYM shares have decreased by 27.8% and is now trading at $1.95.
View the best growth stocks for 2024 here.

How were Eliem Therapeutics' earnings last quarter?

Eliem Therapeutics, Inc. (NASDAQ:ELYM) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.19.

When did Eliem Therapeutics IPO?

Eliem Therapeutics (ELYM) raised $75 million in an initial public offering (IPO) on Tuesday, August 10th 2021. The company issued 6,000,000 shares at a price of $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Who are Eliem Therapeutics' major shareholders?

Top institutional investors of Eliem Therapeutics include Janus Henderson Group PLC (12.12%), Samsara BioCapital LLC (8.77%), Ally Bridge Group NY LLC (4.13%) and Point72 Asset Management L.P. (1.99%). Insiders that own company stock include Ra Capital Management, LP, Valerie Morisset and Emily Pimblett.
View institutional ownership trends.

How do I buy shares of Eliem Therapeutics?

Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Eliem Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eliem Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELYM
• CUSIP: N/A
• CIK: 1768446
• Web: www.eliemtx.com
• Phone: 877-354-3689
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-35,120,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.03%
• Return on Assets: -45.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 60.41
• Quick Ratio: 60.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.90 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 29,752,000
• Free Float: 28,354,000
• Market Cap: $58.02 million
• Optionable: Not Optionable
• Beta: -0.39